Ivantis Hydrus Microstent Beats Glaukos iStent In Glaucoma Study
In the randomized COMPARE trial, eyes treated with Ivantis' Hydrus Microstent were about twice as likely to not need medication than eyes treated with two Glaukos iStent trabecular micro-bypass stents one year after implant The one-year results of the trial have been accepted for publication in Opthalmology.
You may also be interested in...
Glaukos Corp. said it expects rising competition in the US microinvasive glaucoma surgery (MIGS) space in 2020 from Ivantis along with surgical procedures.
It was another record year for novel device approvals by US FDA, driven by the big uptick in de novo classifications for low-to-moderate-risk devices in 2018. Meanwhile, original PMA approvals dropped significantly. An analysis and infographic on FDA device approval trends in 2018.
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.